Truncated Bcl-2, a potential pre-metastatic marker in prostate cancer.
A novel truncated form of Bcl-2, termed Bcl-2psi, was discovered in invasive prostate cancer cells, using laser capture microdissection, RNA-polymerase cycling reaction, and microarray analysis. The expression of Bcl-2psi increased prior to metastasis in higher-grade prostate cancer. The immunoreactive Bcl-2psi was specifically identified in higher-grade prostate cancer cells. These findings suggest that Bcl-2psi may be a potential pre-metastatic marker for detection, diagnosis, and therapy during the initiation of metastasis in prostate cancer.